R12258CP

MLN Connects^® Newsletter Message

CMS Releases Revised Guidance for Medicare Prescription Drug Inflation Rebate Program

On December 14, CMS released revised guidance detailing key requirements and procedures for calculating rebates and invoicing manufacturers that owe rebates to Medicare under the Medicare Prescription Drug Inflation Rebate Program for certain drugs covered under Medicare Part B and Part D. CMS also released the list of 48 prescription drugs for which Part B beneficiary coinsurances may be lower between January 1, 2024 – March 31, 2024. More information about these 48 Part B drugs and biological products can be found in the quarterly Average Sales Price (ASP) public files, available here (PDF). A fact sheet is available here (PDF). 

This coinsurance adjustment applies to certain drugs and biologicals paid under Medicare Part B. The Part B drugs impacted by this coinsurance adjustment may change quarterly. 

More Information:

• Full press release
• Medicare Part B Prescription Drug Inflation Rebate revised guidance (PDF)
• Medicare Part D Prescription Drug Inflation Rebate revised guidance (PDF)
• Medicare Part B Drug Average Sales Price webpage